uplarafenib   Click here for help

GtoPdb Ligand ID: 12882

Synonyms: Compound A [WO2022119905A2]
Compound class: Synthetic organic
Comment: Uplarafenib is the INN for a BRAF inhibitor that was designed as an antineoplastic agent. It is one of the compounds claimed in patent WO2022119905A2 (NeuPharma) [1]. Uplarafenib is likely Henlius/NeuPharma lead BRAF asset HLX208 (RX208), that is designed to target oncogenic BRAFV600E.
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 8
Hydrogen bond donors 1
Rotatable bonds 7
Topological polar surface area 108.81
Molecular weight 494.49
XLogP 1.28
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES CCCS(=O)(=O)NC1=CC(=C(C(=C1F)C(=O)C2=CC=C3C(=C2)N=C(C=N3)N4CCOCC4)F)F
Isomeric SMILES FC1=C(C=C(C(=C1C(=O)C=2C=C3N=C(C=NC3=CC2)N4CCOCC4)F)F)NS(=O)(=O)CCC
InChI InChI=1S/C22H21F3N4O4S/c1-2-9-34(31,32)28-17-11-14(23)20(24)19(21(17)25)22(30)13-3-4-15-16(10-13)27-18(12-26-15)29-5-7-33-8-6-29/h3-4,10-12,28H,2,5-9H2,1H3
InChI Key HAYBWDINAFTFCJ-UHFFFAOYSA-N
No information available.
Summary of Clinical Use Click here for help
HLX208 has been progressed to clinical evaluations to determine efficacy against advanced solid tumours with the BRAFV600E mutation.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT04984369 The Efficacy of HLX208 (BRAF V600E Inhibitor) With Cetuximab for Metastatic Colorectal Cancer (mCRC) With BRAF V600E Mutation After First-line Treatment Phase 2 Interventional Shanghai Henlius Biotech
NCT05114603 A Phase II Clinical Trial to Evaluate HLX208 in Advanced Melanoma Patients With BRAF V600 Mutation Phase 2 Interventional Shanghai Henlius Biotech
NCT05127759 The Efficacy and Safety of HLX208 in Metastatic Colorectal Cancer (mCRC) With BRAF V600E Mutation Phase 2 Interventional Shanghai Henlius Biotech